SE447731B - Spiro-polycykliska imidazolidindionderivat - Google Patents

Spiro-polycykliska imidazolidindionderivat

Info

Publication number
SE447731B
SE447731B SE7909439A SE7909439A SE447731B SE 447731 B SE447731 B SE 447731B SE 7909439 A SE7909439 A SE 7909439A SE 7909439 A SE7909439 A SE 7909439A SE 447731 B SE447731 B SE 447731B
Authority
SE
Sweden
Prior art keywords
naphth
spiro
polycyclic
formula
derivative
Prior art date
Application number
SE7909439A
Other languages
English (en)
Swedish (sv)
Other versions
SE7909439L (sv
Inventor
R Sarges
J Belletire
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SE7909439L publication Critical patent/SE7909439L/xx
Publication of SE447731B publication Critical patent/SE447731B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SE7909439A 1978-11-16 1979-11-15 Spiro-polycykliska imidazolidindionderivat SE447731B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/961,335 US4181728A (en) 1978-11-16 1978-11-16 Spiro-polycyclicimidazolidinedione derivatives

Publications (2)

Publication Number Publication Date
SE7909439L SE7909439L (sv) 1980-05-17
SE447731B true SE447731B (sv) 1986-12-08

Family

ID=25504341

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7909439A SE447731B (sv) 1978-11-16 1979-11-15 Spiro-polycykliska imidazolidindionderivat

Country Status (23)

Country Link
US (1) US4181728A (de)
JP (2) JPS6052157B2 (de)
AR (1) AR222052A1 (de)
AT (1) AT369742B (de)
AU (1) AU515301B2 (de)
BE (1) BE880065A (de)
CA (1) CA1125294A (de)
CH (1) CH642358A5 (de)
DE (1) DE2946037A1 (de)
DK (1) DK484479A (de)
ES (1) ES486007A1 (de)
FI (1) FI66385C (de)
FR (1) FR2441627A1 (de)
GB (1) GB2038315B (de)
IE (1) IE49116B1 (de)
IL (1) IL58730A (de)
IT (1) IT1127231B (de)
LU (1) LU81890A1 (de)
NL (1) NL177689C (de)
PH (1) PH15672A (de)
PT (1) PT70452A (de)
SE (1) SE447731B (de)
YU (1) YU41678B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490381A (en) * 1979-11-13 1984-12-25 Imperial Chemical Industries Plc 1'-Substituted spiro[imidazolidine-4,3'-indoline]2,2',5-triones
EP0065393B1 (de) * 1981-05-12 1984-12-27 Imperial Chemical Industries Plc Pyrrolderivate
US4438272A (en) 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
JPS59500618A (ja) * 1982-04-15 1984-04-12 アルコン・ラボラトリ−ズ・インコ−ポレ−テッド スピロ―フルオロフルオレン化合物、その製造法およびアルド―スレダクターゼ活性を阻害する組成物
US4464385A (en) * 1982-04-15 1984-08-07 Alcon Laboratories, Inc. Treatment of diabetic complications with hydantoins
IL68314A0 (en) * 1982-04-15 1983-07-31 Alcon Lab Inc Method and composition for inhibiting aldose reductase activity and process for preparing spirofluorofluoren and spiro-difluorofluoren compounds
US4436745A (en) 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
US4540700A (en) * 1982-04-15 1985-09-10 Alcon Laboratories, Inc. Treatment of diabetic complications with certain spiro-imidazolidine-diones
DE3342933A1 (de) * 1983-11-26 1985-06-05 Horst G. 5190 Stolberg Schumann Regalfoerderzeug
US4717725A (en) * 1984-04-11 1988-01-05 Alcon Laboratories, Inc. Ophthalmic wound healing with aldose reductase inhibitors
US4600717A (en) * 1984-04-11 1986-07-15 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in ophthalmic wound healing
US4609663A (en) * 1984-09-11 1986-09-02 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in glaucoma therapy
US4576143A (en) * 1984-10-05 1986-03-18 Clark Iii William T Method of immune modification by means of extracorporeal irradiation of the blood
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
US5340829A (en) * 1984-11-20 1994-08-23 Washington Research Foundation Immunoregulatory agents
JPS6372140U (de) * 1986-10-29 1988-05-14
JPS63119451U (de) * 1987-01-30 1988-08-02
EP0536119A4 (en) * 1989-02-10 1993-08-04 Washington Research Foundation Immunoregulatory agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683718A (en) * 1952-01-11 1954-07-13 Searle & Co Spiro-[xanthene-9, 4'-imidazolidine]-2, 5-dione
DE1032257B (de) * 1954-05-27 1958-06-19 Cutter Lab Verfahren zur Herstellung neuer Hydantoine
GB796069A (en) * 1955-12-23 1958-06-04 Ici Ltd Substituted hydantoins
GB818724A (en) * 1956-10-18 1959-08-19 Ici Ltd Hydantoin derivatives
US3532744A (en) * 1967-07-28 1970-10-06 American Home Prod 1- and 2-amino substituted indane and tetralene carboxylic acids
US3821383A (en) * 1972-07-10 1974-06-28 Ayerst Mckenna & Harrison Compositions for and a method of treating diabetic complications
US4078064A (en) * 1976-08-18 1978-03-07 E. R. Squibb & Sons, Inc. 8H-Pyrazolo[4',3':5,6]pyrido[3,4-e][1,2,4]triazolo[1,5-a]pyrimidines
CA1088945A (en) * 1976-10-18 1980-11-04 Pfizer Limited Hydantoin derivatives as therapeutic agents
US4117230A (en) * 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4127665A (en) * 1978-01-18 1978-11-28 Pfizer Inc. Thienohydantoin derivatives

Also Published As

Publication number Publication date
CA1125294A (en) 1982-06-08
DK484479A (da) 1980-05-17
US4181728A (en) 1980-01-01
ATA729779A (de) 1982-06-15
LU81890A1 (fr) 1980-06-05
SE7909439L (sv) 1980-05-17
YU41678B (en) 1987-12-31
YU277379A (en) 1983-01-21
FR2441627B1 (de) 1983-06-03
CH642358A5 (fr) 1984-04-13
FI66385B (fi) 1984-06-29
AR222052A1 (es) 1981-04-15
IL58730A0 (en) 1980-02-29
ES486007A1 (es) 1980-09-01
IE49116B1 (en) 1985-08-07
PH15672A (en) 1983-03-11
FI793586A (fi) 1980-05-17
JPS60120870A (ja) 1985-06-28
JPS6144868B2 (de) 1986-10-04
IT7927311A0 (it) 1979-11-15
PT70452A (en) 1979-12-01
JPS6052157B2 (ja) 1985-11-18
IE792184L (en) 1980-05-16
IL58730A (en) 1984-01-31
JPS5589268A (en) 1980-07-05
GB2038315A (en) 1980-07-23
NL177689C (nl) 1985-11-01
FR2441627A1 (fr) 1980-06-13
FI66385C (fi) 1984-10-10
AU515301B2 (en) 1981-03-26
AU5288079A (en) 1980-05-22
NL7908352A (nl) 1980-05-20
IT1127231B (it) 1986-05-21
BE880065A (fr) 1980-05-16
AT369742B (de) 1983-01-25
DE2946037A1 (de) 1980-05-22
GB2038315B (en) 1982-08-11
NL177689B (nl) 1985-06-03

Similar Documents

Publication Publication Date Title
SE447731B (sv) Spiro-polycykliska imidazolidindionderivat
US4128658A (en) Aminoalkyl furan derivatives
DE60225316T2 (de) Cyanoalkylamino-derivate als protease-hemmer
KR880000968B1 (ko) 1, 2-디아미노 시클로부텐-3, 4-디온 및 그의 제조방법
US4127665A (en) Thienohydantoin derivatives
NO170883B (no) Fremgangsmaate for fremstilling av 2-amino-5-hydroksy-4-metylpyrimidin-derivater
DE60210784T2 (de) Orale antidiabetische wirkstoffe
CS199690B2 (cs) Způsob výroby spiro-hydantoinových derivátů
SE437024B (sv) Forfarande for framstellning av spiro-hydantoinforeningar
WO2000034255A9 (en) Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin
EP0008229B1 (de) Spiro-furanohydantoinderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
US4307106A (en) Aminothiazoles
US7446127B2 (en) Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders
DD264215A5 (de) Verfahren zur herstellung von spiroimidazolidinen
DE68916685T2 (de) Mevalonolactone vom Typ Pyrazolopyridin.
US4169855A (en) N'-derivatives of n-(2-mercapto-ethyl)-2-nitro-1,1-ethenediamine
SU858570A3 (ru) Способ получени производных 3-/тетразол-5-ил/-1-азаксантона или их солей
US4320135A (en) Inhibiting growth hormone secretion with 5,5-substituted hydantoin derivatives
CS254349B2 (en) Method of new substituted isoxazole derivatives production
JP2967231B2 (ja) １，４―チアジン誘導体
KR810000355B1 (ko) 아미노 알킬푸란 유도체의 제조방법
US4772704A (en) 2,5-disubstituted-4(3H)-pyrimidones having histamine H2 -receptor antagonist activity
KR810000356B1 (ko) 아미노 알킬푸란 유도체의 제조방법
DE102005038632B4 (de) Acyltryptophanole
EP0158083A2 (de) Arzneimittel

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7909439-7

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7909439-7

Format of ref document f/p: F